the registry of oncology outcomes associated with testing and treatment

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma

Summary: this study is to collect and validate regulatory-grade real-world data (rwd) in oncology using the novel, master observational trial construct. this data can be then used in real-world evidence (rwe) generation. it will also create reusable infrastructure to allow creation or affiliation with many additional rwd/rwe efforts both prospective and retrospective in nature.

this is a master observational trial (mot). anyone who has been diagnosed with advanced cancer is eligible as long as they are a candidate for treatment. each patient will receive testing and treatment as determined by patient in consultation with physician. root will proceed in two directions: (1) validation cohorts. these patients will demonstrate the ability of the mot to prospectively collect data using the same protocol and related documents, standardized data elements and processes, and accepted scientific endpoints; and (2) analysis cohorts. the modular nature of the study allows collection of rwd ranging from diagnosis only to the full treatment course of the of the patient. patients are grouped to allow focused data collection or a specific analysis. analysis cohorts can be created from patients already enrolled in root or be defined prospectively. because of the ongoing advancements of molecular based oncology, this trial allows a detailed focus on molecular testing as part of any cohort. data is reported by the group that is most qualified to provide this information and is proved, at point of care, using standardized data elements and processes. physicians will report diagnosis, molecular characteristics, staging, disease burden, significant comorbidities, treatment response, and medical decision making. molecular testing (reports and details) will be requested from testing laboratories. any diagnostic films will be received digitally from the location the study was performed. research staff assist in data entry and providing physicians needed data as part of the regular workflow to allow point-of-care reporting. the validation cohorts and analysis cohorts may run sequentially or in parallel with each other.

Eligibility criteria:
inclusion criteria: * patient or representative provides written informed consent * patient is diagnosed with advanced malignancy * patient is willing to be treated for this malignancy according to a plan determine by them and their physician * patient will be willing to have regular follow up visits as part of their standard of care exclusion criteria: * patient is not a candidate or does not desire any treatment for their disease

Keywords: precision medicine molecular sequence data databases, genetic high-throughput nucleotide sequencing massively-parallel sequencing observational study treatment patient outcome assessment adaptive clinical trial molecular typing response rate progression free survival overall survival